Stem Cell Shares Launch on NIH (STEM, GERN, ASTM)

Posted in General 
December 2nd, 2009

We are seeing a sharp run in some of the stem cell stocks after a National Institutes of Health approval on new embryonic stem cell lines.

  • StemCells Inc. (NASDAQ: STEM) up 5.5% at $1.14; 52-week range $0.89 to $3.07; market cap $135 million
  • Geron Corporation (NASDAQ: GERN) up 4.8% at $5.70; 52-week range $3.00 to $9.24; market cap $522 million
  • Aastrom Biosciences, Inc. (NASDAQ: ASTM) up 5.5% at $0.288; 52-week range $0.24 to $0.78; market cap $50 million

We have full coverage of this with the actual explanations and more coverage of related stem cell players that may be indirect beneficiaries over at BioHealthInvestor.com.

JON OGG

1:06 PM EST

Comments are closed

-->